On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
How do mission, vision, and data analysis fit into today's biotech goals? Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Pharmagellan...
Now on the Few & Far Between podcast: Did you know that one in ten people with Type 1 Diabetes (TD1) die from hypoglycemia?...
"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax...